Stock Report: Curis Inc. (CRIS) Report Updated: Nov 16, 2009 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
Rating: Weekly View
| This Week: | A |
|---|---|
| Last Week: | A |
| Two Weeks Ago: | A |
Company Profile
Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor. The company was founded in 2000 and is based in Cambridge, Massachusetts.
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier’s Portfolios
- Blue Chip GrowthTop blue chips
- Global GrowthTop internationals
- Emerging GrowthTop small-caps
- Quantum GrowthFastest-moving
Most Popular Stocks
SQM, AAPL, ABV, GG, BIDU, AMZN, STEC, CTSH, MED, ENI, CEO, SWN, SID, CGA, OXY, BMY


